Clinical trial of long term efficacy for tocilizumab in systemic sclerosis and sclerodermatous chronic GVHD
Not Applicable
- Conditions
- The patients with systemic sclerosis or sclerodermatous chronic GVHD.
- Registration Number
- JPRN-UMIN000022624
- Lead Sponsor
- Kanazawa University Hospital
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up complete
- Sex
- All
- Target Recruitment
- 5
Inclusion Criteria
Not provided
Exclusion Criteria
1.Patients with a history of shock or hypersensitivity to this drug. 2.Patients who are complicated by infectious diseases. 3.Patients with a history of myocardial infarction or unstable angina. 4.Patients with reduced severe bone marrow function. 5.Women who may be pregnant or pregnant. 6.Lactating women
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Evaluate skin score every 4 weeks after treatment(total 116 weeks).
- Secondary Outcome Measures
Name Time Method